Janux Therapeutics (JANX) Receivables - Net (2020 - 2026)

Janux Therapeutics (JANX) has 6 years of Receivables - Net data on file, last reported at $35.0 million in Q1 2026.

• Receivables - Net for Q1 2026 came in at $35.0 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $35.0 million (changed N/A YoY), and the FY2020 annual result was $8.0 million, changed N/A from the prior year.
• Receivables - Net advanced to $35.0 million in Q1 2026 per JANX's latest filing, from $7.5 million in the prior quarter.
• Over five years, Receivables - Net peaked at $35.0 million in Q1 2026 and troughed at $500000.0 in Q3 2022.
• A 4-year average of $8.9 million and a median of $800000.0 in 2023 frame the typical range for Receivables - Net.
• On a YoY basis, Receivables - Net climbed as much as 35.12% in 2024 and fell as far as 35.12% in 2024.
• A 4-year view of Receivables - Net shows it stood at $500000.0 in 2022, then surged by 60.0% to $800000.0 in 2023, then surged by 837.5% to $7.5 million in 2024, then soared by 366.67% to $35.0 million in 2026.
• Business Quant data shows JANX's Receivables - Net at $35.0 million in Q1 2026, $7.5 million in Q2 2024, and $519000.0 in Q1 2024.